Curetis to Present at Several Investor and Scientific Conferences in the Fourth Quarter 2016
Large & MidCap Event, October 5-6, 2016 - Paris, France: one-on-one meetings.
BIO Investor Forum, October 18-19, 2016 - San Francisco, CA, USA: company presentation and one-on-one meetings.
DKOU 2016 (German Congress of Orthopedics and Traumatology), October 25-28, 2016 - Berlin, Germany: scientific meeting. Exhibition booth Hall 2.2-71. Joint symposium with Heraeus Medical, October 27, 2016, at 1:00 pm, room Berlin 2.
SOFCOT 2016 (Congress of the French Society of Orthopedic Surgery & Traumatology), November 8-11, 2016 - Paris, France: scientific meeting. Exhibition booth no. 5952.
AMP 2016 (Association for Molecular Pathology), November 11-12, 2016 - Charlotte, NC, USA: scientific meeting. Exhibition booth no. T13C.
Jefferies 2016 London Healthcare Conference, November 16-17, 2016 - London, United Kingdom: one-on-one meetings.
Biotech and Money Inv€$tival Showcase, November 18, 2016 - London, United Kingdom: company presentation and one-on-one meetings.
This document constitutes neither an offer to buy nor to subscribe securities and neither this document nor any part of it should form the basis of any investment decision in Curetis.
The information contained in this press release has been carefully prepared. However, Curetis bears and assumes no liability of whatever kind for the correctness and completeness of the information provided herein. Curetis does not assume an obligation of whatever kind to update or correct information contained in this press release whether as a result of new information, future events or for other reasons.
This press release includes statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes", "estimates", "anticipates", "expects", "intends", "may", "will", or "should", and include statements Curetis makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. Curetis' actual results may differ materially from those predicted by the forward-looking statements. Curetis undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.
Founded in 2007, Curetis is a molecular diagnostics company which focuses on the development and commercialization of reliable, fast and cost-effective products for diagnosing severe infectious diseases. The diagnostic solutions of Curetis enable rapid multi-parameter pathogen and antibiotic resistance marker detection in only a few hours, a process that today can take up to days or even weeks with other techniques.
To date, Curetis has raised EUR 44.3 million in an IPO on Euronext Amsterdam and Euronext Brussels and private equity funds of over EUR 63.5 million. The company is based in Holzgerlingen near Stuttgart, Germany. Curetis has signed collaboration agreements with Heraeus Medical and Cempra Inc. as well as several international distribution agreements covering many countries across Europe, the Middle East and Asia.
For further information, please visit www.curetis.com.